Hyperandrogenism as a side effect of anticonvulsants
https://doi.org/10.17749/2077-8333.2018.10.2.043-050
Abstract
Aim: confirm the connection between hyperandrogenism and side effects of antiepileptic drugs in women. Materials and
Methods. Body weight, the menstrual cycle periodicity and the blood concentration of dihydrotestosterone were monitored in 278 women taking various antiepileptic drugs (valproic acid, carbamazepine, lamotrigine, topiramate, and levetiracetam). The measurements were made at 3, 6, and 12 month after the treatment began.
Results. Among women taking valproic acid for 12 months, the average weight gain was 14.4%, and in the group of carbamazepine – 5.4%. In women taking lamotrigine and levetiracetam, the weight gain did not exceed 1.2%. With topiramate, a decrease in the body weight by 1.4% was found. Among women taking valproic acid, the occurrence rate of menstrual cycle disorders increased by 64.9% after 12 months of treatment. In women taking carbamazepine the increase was 22.6%. In the other groups, this increase did not exceed 3.7%. The occurrence of menstrual cycle disorders correlated with an increase in the level of dihydrotestosterone. In women taking valproic acid, an increase in the concentration of blood dihydrotestosterone from 256.8 pg/ml to 526.32 pg/ml was found at the time-point of 12 months. In the group taking carbamazepine, an increase in the concentration of dihydrotestosterone from 268.4 pg/ml to 354.4 pg/ml was noted. In the other groups, fluctuations in the concentration of dihydrotestosterone were insignificant.
Conclusion. The body weight gain and the menstrual cycle disorders during anticonvulsant therapy are associated with hyperandrogenism.
About the Authors
E. V. Tsallagova
Research Center for Obstetrics, Gynecology and Perinatology named after V. I. Kulakov of the Ministry of Health of Russian Federation
Russian Federation
Russian Federation
4 akademika Oparina Str., Moscow 117198, Russia
MD, PhD, obstetrician-gynecologist, Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of the Russian Federation
V. O. Generalov
Research Center for Obstetrics, Gynecology and Perinatology named after V. I. Kulakov of the Ministry of Health of Russian Federation
Russian Federation
Russian Federation
4 akademika Oparina Str., Moscow 117198, Russia
MD, PhD, Neurologist, Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of the Russian Federation
T. R. Sadykov
Center of diagnostics and treatment for epilepsy «Planeta Med»
Russian Federation
Russian Federation
13-2 Varshavskoe shosse, Moscow 117105, Russia
MD, PhD, Neurologist, Planeta Med – Center for Diagnostics and Treatment of Epilepsy, Tel.: +7(495)509-27-59
References
1. Chazova I. E., Mychka V. B. Metabolic syndrome [Metabolicheskij sindrom (in Russian)]. Moscow. 2004; 168s.
2. Isojarvi J. I., Taubøll E., Tapanainen J. S. et al. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia. 2001; 42 (3): 305-10.
3. Verrotti A., Basciani F., De Simone M. et al. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol. 2002; 17 (4): 265-8.
4. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs. 2003; 17 (11): 781-91.
5. Corman C. L., Leung N. M., Guberman A. H. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci. 1977; 24 (3): 240-4.
6. Garoufi A., Vartzelis G., Tsentidis C. Epilepsy Res. 2016 May; 122: 110-3.
7. DeToledo J.C., Toledo C., DeCerce J. et al. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit. 1997; 19 (4): 394-6.
8. Cabrera J., Emir B., Dills D. et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin. 2012; 28 (6): 1027- 37.
9. Pickrell W. O., Lacey A. S., Thomas R. H. et al. Weight change associated with antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013 Jul; 84 (7): 796-9.
10. Morrell M. J. Epilepsy in women. Am Fam Physician. 2002 Oct 15; 66 (8): 1489-94.
11. Uvarova E. V. Lechashchij vrach (in Russian). 2008; 3: 34-42.
12. Filatova N. V. Features of epilepsy in women with menstrual dysfunction. PhD diss. [Osobennosti epilepsii u zhenshchin s narusheniem menstrual’noj funkcii. Avtoref. diss …kand. med. nauk. (in Russian)]. Moscow. 2010.
13. Morrell M. J., Hayes F. J. High incidence of components of polycystic ovary syndrome in young women with epilepsy treated with valproate versus lamotrigine. Epilepsia. 2005; 46 (8): 88.
14. Morrell M. J., Hayes F. J., Sluss P. M. et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol. 2008 Aug; 64 (2): 200-11.
15. Hamed S. A. Antiepileptic drugs influences on body weight in people with epilepsy. Expert Rev. Clin. Pharmacol. 2015; 8 (1): 103-114.
Review
For citations:
Tsallagova E.V., Generalov V.O., Sadykov T.R. Hyperandrogenism as a side effect of anticonvulsants. Epilepsy and paroxysmal conditions. 2018;10(2):43-50. (In Russ.) https://doi.org/10.17749/2077-8333.2018.10.2.043-050
Views: 1897
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
